AAVX.F Stock Overview
A clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
ABIVAX Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €7.21 |
| 52 Week High | €11.05 |
| 52 Week Low | €5.81 |
| Beta | 1.58 |
| 1 Month Change | 4.34% |
| 3 Month Change | 22.41% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -70.33% |
| Change since IPO | -18.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| AAVX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -7.7% | 1.2% |
| 1Y | n/a | -13.5% | 7.7% |
Return vs Industry: Insufficient data to determine how AAVX.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how AAVX.F performed against the US Market.
Price Volatility
| AAVX.F volatility | |
|---|---|
| AAVX.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.8% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: AAVX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AAVX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 69 | Marc M. de Garidel | www.abivax.com |
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme Fundamentals Summary
| AAVX.F fundamental statistics | |
|---|---|
| Market cap | US$428.01m |
| Earnings (TTM) | -US$198.94m |
| Revenue (TTM) | US$12.18m |
35.1x
P/S Ratio-2.2x
P/E RatioIs AAVX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AAVX.F income statement (TTM) | |
|---|---|
| Revenue | €10.79m |
| Cost of Revenue | €0 |
| Gross Profit | €10.79m |
| Other Expenses | €187.03m |
| Earnings | -€176.24m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Jun 02, 2025
| Earnings per share (EPS) | -2.78 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,633.08% |
| Debt/Equity Ratio | 263.3% |
How did AAVX.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/08 15:45 |
| End of Day Share Price | 2025/05/01 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ABIVAX Société Anonyme is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Oscar Haffen Lamm | Bryan Garnier & Co |
| Eric Le Berrigaud | Bryan Garnier & Co |
| Julian Harrison | BTIG |